Marker Therapeutics Income Statement 2025-1999 | MRKR

Brief overview of financial results at Marker Therapeutics

The figures are compared over a five-year interval. Revenue reported by Marker Therapeutics was $467 thousand at the beginning of the period and $3.5 million at the end. The five-year change reached +659.8%, while CAGR stood at 50%. Sales grew at a rate typical of a strong expansion phase.

The operating result measured by EBITDA moved from −27.8 million dollars to −12.9 million dollars, or +53.6%. The operating result developed less favorably than sales. The EBITDA share of revenue changed from −5957.8% to −363.5%. Higher profitability strengthens the quality of operating growth.

The final result was −28.7 million dollars initially and −12.2 million dollars in the final year. The direction improved, yet positive earnings are still absent.

Over the period, capitalization shifted from $90 million to $20.5 million (−77.2%). Financial performance is stronger than the share-price trend.

Financial takeaway

The financial profile remains mixed, with strengths and risks moving in different directions. The constructive conclusion rests on a larger revenue base, an improving EBITDA margin and a stronger final result. The main areas of concern are a narrow EBITDA buffer and a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.